Bayer's Off-Label Yaz Marketing Violated FCA: Watchdog

Law360, New York (December 14, 2011, 4:57 PM EST) -- A pharmaceutical company watchdog accused Bayer Schering Pharma AG of marketing its Yasmin and Yaz contraceptives for unapproved purposes and causing doctors to seek Medicaid reimbursements for off-label prescriptions of those drugs, according to court documents unsealed Monday.

In a complaint filed under seal in October 2010 in Texas federal court, relator Pharma Fraud Watch LLC alleges that Bayer violated the False Claims Act by knowingly causing pharmacists and doctors to file false federal government claims by marketing Yaz and Yasmin for uses the U.S. Food...
To view the full article, register now.